Novel MYBL1 Gene Rearrangements with Recurrent MYBL1-NFIB Fusions in Salivary Adenoid Cystic Carcinomas Lacking t(6;9) Translocations

Clinical Cancer Research

Volumn 22, Issue 3, 2016, Pages 725-733

  Mitani, Yoshitsugu ^a   Liu, Bin ^a   Rao, Pulivarthi H ^a   Borra, Vishnupriya J ^b   Zafereo, Mark ^a   Weber, Randal S ^a   Kies, Merrill ^a   Lozano, Guillermina ^a   Andrew Futreal, P ^a   Caulin, Carlos ^a   El Naggar, Adel K ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5' UNTRANSLATED REGION; ADENOID CYSTIC CARCINOMA; ARTICLE; CANCER RECURRENCE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; GENE DELETION; GENE EXPRESSION REGULATION; GENE FUSION; GENE INTERACTION; GENE REARRANGEMENT; GENE SEQUENCE; GENE TRANSLOCATION; HUMAN; HUMAN TISSUE; MICROARRAY ANALYSIS; MYBL1 GENE; NFIB GENE; PRIORITY JOURNAL; SALIVARY GLAND CARCINOMA; UPREGULATION; VALIDATION PROCESS; CHROMOSOME 8; CHROMOSOME 9; CHROMOSOME BREAKAGE; CLUSTER ANALYSIS; FEMALE; GENE EXPRESSION PROFILING; GENE ORDER; GENETICS; GENOMICS; HIGH THROUGHPUT SEQUENCING; HUMAN GENOME; MALE; MORTALITY; PATHOLOGY; PROCEDURES; PROGNOSIS; REPRODUCIBILITY; SALIVARY GLAND TUMOR;

MYBL1 PROTEIN, HUMAN; NFIB PROTEIN, HUMAN; NUCLEAR FACTOR I; ONCOPROTEIN; TRANSACTIVATOR PROTEIN;

CARCINOMA, ADENOID CYSTIC; CHROMOSOME BREAKPOINTS; CHROMOSOMES, HUMAN, PAIR 8; CHROMOSOMES, HUMAN, PAIR 9; CLUSTER ANALYSIS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE ORDER; GENOME, HUMAN; GENOMICS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MALE; NFI TRANSCRIPTION FACTORS; ONCOGENE PROTEINS, FUSION; PROGNOSIS; PROTO-ONCOGENE PROTEINS; REPRODUCIBILITY OF RESULTS; SALIVARY GLAND NEOPLASMS; TRANS-ACTIVATORS; TRANSLOCATION, GENETIC;

EID: 84957087778     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-2867-T     Document Type: Article

References (26)

1. Chomette G, AuriolM, Tranbaloc P, Vaillant JM. Adenoid cystic carcinoma of minor salivary glands. Analysis of 86 cases. Clinicopathological, histoenzymological and ultrastructural studies. Virchows Arch A Pathol Anat Histol 1982;395:289-301.
2. Batsakis JG, Luna MA, el-Naggar A. Histopathologic grading of salivary gland neoplasms: III. Adenoid cystic carcinomas. Ann Otol Rhinol Laryngol 1990;99:1007-9.
3. Locati LD, Bossi P, Perrone F, Potepan P, Crippa F, Mariani L, et al. Cetuximab in recurrent and/or metastatic salivary gland carcinomas: a phase II study. Oral Oncol 2009;45:574-8.
4. Seaver PR Jr, Kuehn PG. Adenoid cystic carcinoma of the salivary glands. A study of ninety-three cases. Am J Surg 1979;137:449-55.
5. Fordice J, Kershaw C, El-Naggar A, Goepfert H. Adenoid cystic carcinoma of the head and neck: predictors of morbidity and mortality. Arch Otolaryngol-Head Neck Surg 1999;125:149-52.
6. Laurie SA, Licitra L. Systemic therapy in the palliative management of advanced salivary gland cancers. J Clin Oncol 2006;24:2673-8.
7. Ho AS, Kannan K, Roy DM, Morris LG, Ganly I, Katabi N, et al. The mutational landscape of adenoid cystic carcinoma. Nat Genet 2013;45: 791-8.
8. Stephens PJ, Davies HR, Mitani Y, Van Loo P, Shlien A, Tarpey PS, et al. Whole exome sequencing of adenoid cystic carcinoma. J Clin Invest 2013;123:2965-8.
9. Persson M, Andren Y, Mark J, HorlingsHM, Persson F, Stenman G. Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck. Proc Natl Acad Sci U S A 2009;106:18740-4.
10. Mitani Y, Li J, Rao PH, Zhao YJ, Bell D, Lippman SM, et al. Comprehensive analysis of theMYB-NFIB gene fusion in salivary adenoid cystic carcinoma: incidence, variability, and clinicopathologic significance. Clin Cancer Res 2010;16:4722-31.
11. Mitani Y, Rao PH, Futreal PA, Roberts DB, Stephens PJ, Zhao YJ, et al. Novel chromosomal rearrangements and break points at the t(6;9) in salivary adenoid cystic carcinoma: association with MYB-NFIB chimeric fusion, MYB expression, and clinical outcome. Clin Cancer Res 2011;17:7003-14.
12. West RB, Kong C, Clarke N, Gilks T, Lipsick JS, Cao H, et al. MYB expression and translocation in adenoid cystic carcinomas and other salivary gland tumors with clinicopathologic correlation. Am J Surg Pathol 2011;35:92-9.
13. Drmanac R, Sparks AB, Callow MJ, Halpern AL, Burns NL, Kermani BG, et al. Human genome sequencing using unchained base reads on selfassembling DNA nanoarrays. Science 2010;327:78-81.
14. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res 2015;43:e47.
15. Subramanian A, Tamayo P, Mootha VK,Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005;102:15545-50.
16. Rushton JJ, Davis LM, Lei W, Mo X, Leutz A, Ness SA. Distinct changes in gene expression induced by A-Myb, B-Myb and c-Myb proteins. Oncogene 2003;22:308-13.
17. Ness SA. Myb protein specificity: evidence of a context-specific transcription factor code. Blood Cells Mol Dis 2003;31:192-200.
18. Ramkissoon LA, Horowitz PM, Craig JM, Ramkissoon SH, Rich BE, Schumacher SE, et al. Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1. Proc Natl Acad Sci U S A 2013;110:8188-93.
19. Meaburn KJ, Misteli T, Soutoglou E. Spatial genome organization in the formation of chromosomal translocations. Semin Cancer Biol 2007;17: 80-90.
20. Dini PW, Eltman JT, Lipsick JS. Mutations in the DNA-binding and transcriptional activation domains of v-Myb cooperate in transformation. J Virol 1995;69:2515-24.
21. Gonda TJ, Buckmaster C, Ramsay RG. Activation of c-myb by carboxyterminal truncation: relationship to transformation of murine haemopoietic cells in vitro. EMBO J 1989;8:1777-83.
22. Lei W, Rushton JJ, Davis LM, Liu F, Ness SA. Positive and negative determinants of target gene specificity in myb transcription factors. J Biol Chem 2004;279:29519-27.
23. Brayer KJ, Frerich CA, Kang H, Ness SA. Recurrent Fusions in MYB and MYBL1 Define a Common, Transcription Factor-Driven Oncogenic Pathway in Salivary Gland Adenoid Cystic Carcinoma. Cancer Discovery. 2015 Dec 2. [Epub ahead of print].
24. Zhang J, Wu G, Miller CP, Tatevossian RG, Dalton JD, Tang B, et al. Wholegenome sequencing identifies genetic alterations in pediatric low-grade gliomas. Nat Genet 2013;45:602-12.
25. Gao R, Cao C, Zhang M, Lopez MC, Yan Y, Chen Z, et al. A unifying gene signature for adenoid cystic cancer identifies parallel MYB-dependent and MYB-independent therapeutic targets. Oncotarget 2014;5:12528-42.
26. Moskaluk CA, Baras AS, Mancuso SA, Fan H, Davidson RJ, Dirks DC, et al. Development and characterization of xenograftmodel systems for adenoid cystic carcinoma. Lab Invest 2011;91:1480-90.